The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2018 | Immuno-oncology focus: questions to be answered
A key subject on everyone’s mind at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, was immuno-oncology (IO): predictive testing, combinations, trials, new targets; the list goes on. Speaking from the meeting, Keith Kerr, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, gave us his thoughts on this exciting topic. Dr Kerr highlighted a number of interesting questions, including whether IO is for all patients or not, the affordability of regimens, and if clinicians should use all agents in the first-line setting.
